Empagliflozin alleviates ethanol‐induced cardiomyocyte injury through inhibition of mitochondrial apoptosis via a SIRT1/PTEN/Akt pathway
Sign Up to like & getrecommendations! Published in 2021 at "Clinical and Experimental Pharmacology and Physiology"
DOI: 10.1111/1440-1681.13470
Abstract: Ethanol‐induced myocardial injury involves multiple pathophysiological processes including apoptosis. Empagliflozin (EMPA), is a novel hypoglycaemic drug which possesses multiple pharmacologically relevant protective effects, including anti‐apoptotic, anti‐inflammatory and antioxidant effects. However, whether EMPA treatment has a… read more here.
Keywords: empa; induced myocardial; apoptosis; ethanol induced ... See more keywords
Abstract 4121527: Empagliflozin Improves Mitochondrial Biogenesis in Pulmonary Arterial Hypertension
Sign Up to like & getrecommendations! Published in 2024 at "Circulation"
DOI: 10.1161/circ.150.suppl_1.4121527
Abstract: Background: Pulmonary arterial hypertension (PAH) is a devastating disease characterized by endothelial proliferation and progressive pulmonary vascular (PV) remodeling. Empagliflozin (EMPA), a sodium glucose cotransporter 2 (SGLT2) inhibitor, benefits heart failure patients, potentially mediated by… read more here.
Keywords: pah; sglt2; mitochondrial biogenesis; pulmonary arterial ... See more keywords
Abstract TP371: Effects of Empagliflozin on Ischemic Stroke in a Rat Model: Time-Frequency Electroencephalogram Features and Cerebral Infarction Size
Sign Up to like & getrecommendations! Published in 2025 at "Stroke"
DOI: 10.1161/str.56.suppl_1.tp371
Abstract: Background: Emerging evidence suggests that empagliflozin (EMPA) may offer additional benefits beyond its primary use in diabetes. Ischemic stroke is known to cause distinctive alterations in EEG signals. However, the influences of EMPA on the… read more here.
Keywords: ischemic stroke; time frequency; cerebral infarction; infarction ... See more keywords
Empagliflozin Decreases Lactate Generation in an NHE-1 Dependent Fashion and Increases α-Ketoglutarate Synthesis From Palmitate in Type II Diabetic Mouse Hearts
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Cardiovascular Medicine"
DOI: 10.3389/fcvm.2020.592233
Abstract: Aims/hypothesis: Changes in cardiac metabolism and ion homeostasis precede and drive cardiac remodeling and heart failure development. We previously demonstrated that sodium/glucose cotransporter 2 inhibitors (SGLT2i's) have direct cardiac effects on ion homeostasis, possibly through… read more here.
Keywords: empa; mouse hearts; lactate generation; palmitate ... See more keywords
Sodium–Glucose cotransporter 2 inhibitor empagliflozin decreases ventricular arrhythmia susceptibility by alleviating electrophysiological remodeling post-myocardial-infarction in mice
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.988408
Abstract: Background: Recent clinical trials indicate that sodium–glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in myocardial infarction (MI) patients, but the underlying mechanisms remain unknown. As arrhythmia often occurs during myocardial infarction, it is the… read more here.
Keywords: empa; infarction mice; myocardial infarction; mice ... See more keywords
The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceuticals"
DOI: 10.3390/ph15121516
Abstract: Non-alcoholic fatty liver disease (NAFLD) is related to metabolic syndrome via insulin resistance, where preventing disease progression is crucial in the management process. The study included 240 NAFLD patients with type 2 diabetes who were… read more here.
Keywords: liver; fatty liver; steatosis; empa ... See more keywords
Treatment Outcomes of Graded Dose of Empagliflozin in Type-2 Diabetes: A Real World Study
Sign Up to like & getrecommendations! Published in 2022 at "Annals of African Medicine"
DOI: 10.4103/aam.aam_69_20
Abstract: Background: Costs are important cause of therapeutic noncompliance in type-2 diabetes mellitus (T2DM). Half-tablet empagliflozin (EMPA)-25 mg has lowest monthly cost among all EMPA preparations; data is unavailable on efficacy of half EMPA-25. This study… read more here.
Keywords: empa; group; half; type diabetes ... See more keywords